Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 97 to 102 of 102 entries
Sorted by: Best Match Show Resources per page
NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment.

Frontiers in immunology

Pontarini E, Sciacca E, Grigoriadou S, Rivellese F, Lucchesi D, Fossati-Jimack L, Coleby R, Chowdhury F, Calcaterra F, Tappuni A, Lewis MJ, Fabris M, Quartuccio L, Bella SD, Bowman S, Pitzalis C, Mavilio D, De Vita S, Bombardieri M.
PMID: 34594326
Front Immunol. 2021 Sep 14;12:706737. doi: 10.3389/fimmu.2021.706737. eCollection 2021.

Primary Sjögren's syndrome (pSS) is a chronic autoimmune disease resulting from the inflammatory infiltration of exocrine glands, mainly salivary and lacrimal glands, leading to secretory dysfunction and serious complications including debilitating fatigue, systemic autoimmunity, and lymphoma. Like other autoimmune...

Cite
Pontarini E, Sciacca E, Grigoriadou S, et al. NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment. Front Immunol. 2021;12:706737doi: 10.3389/fimmu.2021.706737.
Pontarini, E., Sciacca, E., Grigoriadou, S., Rivellese, F., Lucchesi, D., Fossati-Jimack, L., Coleby, R., Chowdhury, F., Calcaterra, F., Tappuni, A., Lewis, M. J., Fabris, M., Quartuccio, L., Bella, S. D., Bowman, S., Pitzalis, C., Mavilio, D., De Vita, S., & Bombardieri, M. (2021). NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment. Frontiers in immunology, 12706737. https://doi.org/10.3389/fimmu.2021.706737
Pontarini, Elena, et al. "NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment." Frontiers in immunology vol. 12 (2021): 706737. doi: https://doi.org/10.3389/fimmu.2021.706737
Pontarini E, Sciacca E, Grigoriadou S, Rivellese F, Lucchesi D, Fossati-Jimack L, Coleby R, Chowdhury F, Calcaterra F, Tappuni A, Lewis MJ, Fabris M, Quartuccio L, Bella SD, Bowman S, Pitzalis C, Mavilio D, De Vita S, Bombardieri M. NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment. Front Immunol. 2021 Sep 14;12:706737. doi: 10.3389/fimmu.2021.706737. eCollection 2021. PMID: 34594326; PMCID: PMC8477027.
Copy Download .nbib Format: NLM
Novel Therapeutic Delivery of Nanocurcumin in Central Nervous System Related Disorders.

Nanomaterials (Basel, Switzerland)

Panzarini E, Mariano S, Tacconi S, Carata E, Tata AM, Dini L.
PMID: 33374979
Nanomaterials (Basel). 2020 Dec 22;11(1). doi: 10.3390/nano11010002.

Nutraceuticals represent complementary or alternative beneficial products to the expensive and high-tech therapeutic tools in modern medicine. Nowadays, their medical or health benefits in preventing or treating different types of diseases is widely accepted, due to fewer side effects...

Cite
Panzarini E, Mariano S, Tacconi S, et al. Novel Therapeutic Delivery of Nanocurcumin in Central Nervous System Related Disorders. Nanomaterials (Basel). 2020;11(1)doi: 10.3390/nano11010002.
Panzarini, E., Mariano, S., Tacconi, S., Carata, E., Tata, A. M., & Dini, L. (2020). Novel Therapeutic Delivery of Nanocurcumin in Central Nervous System Related Disorders. Nanomaterials (Basel, Switzerland), 11(1), . https://doi.org/10.3390/nano11010002
Panzarini, Elisa, et al. "Novel Therapeutic Delivery of Nanocurcumin in Central Nervous System Related Disorders." Nanomaterials (Basel, Switzerland) vol. 11,1 (2020). doi: https://doi.org/10.3390/nano11010002
Panzarini E, Mariano S, Tacconi S, Carata E, Tata AM, Dini L. Novel Therapeutic Delivery of Nanocurcumin in Central Nervous System Related Disorders. Nanomaterials (Basel). 2020 Dec 22;11(1). doi: 10.3390/nano11010002. PMID: 33374979; PMCID: PMC7822042.
Copy Download .nbib Format: NLM
Long-term (18 Years) Results of Patients With Long-segment Barrett's Esophagus Submitted to Acid Suppression-duodenal Diversion Operation: Better Than Nissen Fundoplication?.

Annals of surgery

Csendes A, Orellana O, Figueroa M, Lanzarini E.
PMID: 33470631
Ann Surg. 2021 Jan 19; doi: 10.1097/SLA.0000000000004760. Epub 2021 Jan 19.

OBJECTIVE: To determine late results of AS-DD procedure in long-segment (LSBE) and extralong-segment BE (ELSBE) using subjective and objective measurements to ascertain the histological impact over intestinal metaplasia (IM) and progression to EAC.SUMMARY OF BACKGROUND DATA: Barrett esophagus (BE)...

Cite
Csendes A, Orellana O, Figueroa M, et al. Long-term (18 Years) Results of Patients With Long-segment Barrett's Esophagus Submitted to Acid Suppression-duodenal Diversion Operation: Better Than Nissen Fundoplication?. Ann Surg. 2021;doi: 10.1097/SLA.0000000000004760.
Csendes, A., Orellana, O., Figueroa, M., & Lanzarini, E. (2021). Long-term (18 Years) Results of Patients With Long-segment Barrett's Esophagus Submitted to Acid Suppression-duodenal Diversion Operation: Better Than Nissen Fundoplication?. Annals of surgery, . https://doi.org/10.1097/SLA.0000000000004760
Csendes, Attila, et al. "Long-term (18 Years) Results of Patients With Long-segment Barrett's Esophagus Submitted to Acid Suppression-duodenal Diversion Operation: Better Than Nissen Fundoplication?." Annals of surgery vol. (2021). doi: https://doi.org/10.1097/SLA.0000000000004760
Csendes A, Orellana O, Figueroa M, Lanzarini E. Long-term (18 Years) Results of Patients With Long-segment Barrett's Esophagus Submitted to Acid Suppression-duodenal Diversion Operation: Better Than Nissen Fundoplication?. Ann Surg. 2021 Jan 19; doi: 10.1097/SLA.0000000000004760. Epub 2021 Jan 19. PMID: 33470631.
Copy Download .nbib Format: NLM
Clinical effects of preemptive intra-articular lidocaine, dexmedetomidine and lidocaine-dexmedetomidine administration in dogs undergoing arthroscopy.

Veterinary journal (London, England : 1997)

Brioschi FA, Gioeni D, Lazzarini E, Del Prete G, Bronzo V, Jacchetti A, Carotenuto AM.
PMID: 34391917
Vet J. 2021 Oct;276:105730. doi: 10.1016/j.tvjl.2021.105730. Epub 2021 Aug 12.

This study investigated the perioperative effects of preemptive intra-articular lidocaine (L group), dexmedetomidine (D group) and lidocaine-dexmedetomidine (LD group) in dogs. Physiological variables were intraoperatively recorded at 5 min intervals starting from baseline (5 min before intra-articular injection). If...

Cite
Brioschi FA, Gioeni D, Lazzarini E, et al. Clinical effects of preemptive intra-articular lidocaine, dexmedetomidine and lidocaine-dexmedetomidine administration in dogs undergoing arthroscopy. Vet J. 2021;276:105730doi: 10.1016/j.tvjl.2021.105730.
Brioschi, F. A., Gioeni, D., Lazzarini, E., Del Prete, G., Bronzo, V., Jacchetti, A., & Carotenuto, A. M. (2021). Clinical effects of preemptive intra-articular lidocaine, dexmedetomidine and lidocaine-dexmedetomidine administration in dogs undergoing arthroscopy. Veterinary journal (London, England : 1997), 276105730. https://doi.org/10.1016/j.tvjl.2021.105730
Brioschi, F A, et al. "Clinical effects of preemptive intra-articular lidocaine, dexmedetomidine and lidocaine-dexmedetomidine administration in dogs undergoing arthroscopy." Veterinary journal (London, England : 1997) vol. 276 (2021): 105730. doi: https://doi.org/10.1016/j.tvjl.2021.105730
Brioschi FA, Gioeni D, Lazzarini E, Del Prete G, Bronzo V, Jacchetti A, Carotenuto AM. Clinical effects of preemptive intra-articular lidocaine, dexmedetomidine and lidocaine-dexmedetomidine administration in dogs undergoing arthroscopy. Vet J. 2021 Oct;276:105730. doi: 10.1016/j.tvjl.2021.105730. Epub 2021 Aug 12. PMID: 34391917.
Copy Download .nbib Format: NLM
Sedative Effects of Intramuscular Dexmedetomidine and Ketamine at Sub-Anesthetic Dose Alone or in Combination with Methadone in Healthy Dogs.

Topics in companion animal medicine

Lazzarini E, Gioeni D, Del Prete G, Brioschi F, Agostinetto G, Carotenuto A.
PMID: 34400381
Top Companion Anim Med. 2021 Aug 14;45:100579. doi: 10.1016/j.tcam.2021.100579. Epub 2021 Aug 14.

The aim of the present study was to compare sedation quality and cardiorespiratory parameters in healthy dogs after intramuscular injection of dexmedetomidine and ketamine with or without methadone. Forty client-owned dogs were randomly divided into two groups and received...

Cite
Lazzarini E, Gioeni D, Del Prete G, et al. Sedative Effects of Intramuscular Dexmedetomidine and Ketamine at Sub-Anesthetic Dose Alone or in Combination with Methadone in Healthy Dogs. Top Companion Anim Med. 2021;45:100579doi: 10.1016/j.tcam.2021.100579.
Lazzarini, E., Gioeni, D., Del Prete, G., Brioschi, F., Agostinetto, G., & Carotenuto, A. (2021). Sedative Effects of Intramuscular Dexmedetomidine and Ketamine at Sub-Anesthetic Dose Alone or in Combination with Methadone in Healthy Dogs. Topics in companion animal medicine, 45100579. https://doi.org/10.1016/j.tcam.2021.100579
Lazzarini, Eleonora, et al. "Sedative Effects of Intramuscular Dexmedetomidine and Ketamine at Sub-Anesthetic Dose Alone or in Combination with Methadone in Healthy Dogs." Topics in companion animal medicine vol. 45 (2021): 100579. doi: https://doi.org/10.1016/j.tcam.2021.100579
Lazzarini E, Gioeni D, Del Prete G, Brioschi F, Agostinetto G, Carotenuto A. Sedative Effects of Intramuscular Dexmedetomidine and Ketamine at Sub-Anesthetic Dose Alone or in Combination with Methadone in Healthy Dogs. Top Companion Anim Med. 2021 Aug 14;45:100579. doi: 10.1016/j.tcam.2021.100579. Epub 2021 Aug 14. PMID: 34400381.
Copy Download .nbib Format: NLM
Movement disorders in patients with Rett syndrome: A systematic review of evidence and associated clinical considerations.

Psychiatry and clinical neurosciences

Singh J, Lanzarini E, Nardocci N, Santosh P.
PMID: 34472659
Psychiatry Clin Neurosci. 2021 Dec;75(12):369-393. doi: 10.1111/pcn.13299. Epub 2021 Oct 21.

AIM: This systematic review identified and thematically appraised clinical evidence of movement disorders in patients with Rett syndrome (RTT).METHOD: Using PRISMA criteria, six electronic databases were searched from inception to April 2021. A thematic analysis was then undertaken on...

Cite
Singh J, Lanzarini E, Nardocci N, et al. Movement disorders in patients with Rett syndrome: A systematic review of evidence and associated clinical considerations. Psychiatry Clin Neurosci. 2021;75(12):369-393doi: 10.1111/pcn.13299.
Singh, J., Lanzarini, E., Nardocci, N., & Santosh, P. (2021). Movement disorders in patients with Rett syndrome: A systematic review of evidence and associated clinical considerations. Psychiatry and clinical neurosciences, 75(12), 369-393. https://doi.org/10.1111/pcn.13299
Singh, Jatinder, et al. "Movement disorders in patients with Rett syndrome: A systematic review of evidence and associated clinical considerations." Psychiatry and clinical neurosciences vol. 75,12 (2021): 369-393. doi: https://doi.org/10.1111/pcn.13299
Singh J, Lanzarini E, Nardocci N, Santosh P. Movement disorders in patients with Rett syndrome: A systematic review of evidence and associated clinical considerations. Psychiatry Clin Neurosci. 2021 Dec;75(12):369-393. doi: 10.1111/pcn.13299. Epub 2021 Oct 21. PMID: 34472659.
Copy Download .nbib Format: NLM
Showing 97 to 102 of 102 entries